Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Modalis Therapeutics Corporation ( (JP:4883) ).
Modalis Therapeutics Corporation has entered into a license agreement with The Broad Institute to advance gene therapy for LAMA2-related muscular dystrophy. This agreement grants Modalis a non-exclusive, worldwide license to intellectual property that will aid in the development of MDL-101, an AAV-based gene therapy targeting LAMA2 deficiency. The collaboration with Broad Institute enhances Modalis’s intellectual property position and accelerates the development of transformative treatments for MDC1A, potentially benefiting patients with LAMA2-CMD.
More about Modalis Therapeutics Corporation
Modalis Therapeutics Corporation, founded in 2016, is a pioneering leader in epigenetic medicine, focusing on developing therapeutics for serious genetic disorders including neuromuscular diseases, CNS diseases, and cardiomyopathies. The company operates research and development activities in Massachusetts, USA, and utilizes its proprietary CRISPR-GNDM technology to modulate gene expression without causing DNA breaks.
Average Trading Volume: 4,425,679
Technical Sentiment Signal: Sell
Current Market Cap: Yen6.23B
See more insights into 4883 stock on TipRanks’ Stock Analysis page.